- Home
- CLSD vs IMRX Comparison
CLSD vs IMRX Comparison
Compare CLSD & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- IMRX
- Stock Information
- Founded
- CLSD 2011
- IMRX 2008
- Country
- CLSD United States
- IMRX United States
- Employees
- CLSD N/A
- IMRX N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CLSD Health Care
- IMRX Health Care
- Exchange
- CLSD Nasdaq
- IMRX Nasdaq
- Market Cap
- CLSD 69.0M
- IMRX 52.2M
- IPO Year
- CLSD 2016
- IMRX 2021
- Fundamental
- Price
- CLSD $0.76
- IMRX $1.71
- Analyst Decision
- CLSD Strong Buy
- IMRX Strong Buy
- Analyst Count
- CLSD 5
- IMRX 3
- Target Price
- CLSD $4.80
- IMRX $15.33
- AVG Volume (30 Days)
- CLSD 161.6K
- IMRX 244.7K
- Earning Date
- CLSD 05-14-2025
- IMRX 05-05-2025
- Dividend Yield
- CLSD N/A
- IMRX N/A
- EPS Growth
- CLSD N/A
- IMRX N/A
- EPS
- CLSD N/A
- IMRX N/A
- Revenue
- CLSD $3,764,000.00
- IMRX N/A
- Revenue This Year
- CLSD N/A
- IMRX N/A
- Revenue Next Year
- CLSD $476.77
- IMRX N/A
- P/E Ratio
- CLSD N/A
- IMRX N/A
- Revenue Growth
- CLSD N/A
- IMRX N/A
- 52 Week Low
- CLSD $0.70
- IMRX $1.00
- 52 Week High
- CLSD $1.65
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- CLSD 34.26
- IMRX 63.15
- Support Level
- CLSD $0.77
- IMRX $1.58
- Resistance Level
- CLSD $0.91
- IMRX $1.85
- Average True Range (ATR)
- CLSD 0.06
- IMRX 0.14
- MACD
- CLSD -0.01
- IMRX 0.05
- Stochastic Oscillator
- CLSD 5.82
- IMRX 81.33
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.